Research programme: methyltransferase inhbitors - Domainex

Drug Profile

Research programme: methyltransferase inhbitors - Domainex

Latest Information Update: 19 Feb 2013

Price : $50

At a glance

  • Originator Domainex
  • Class Small molecules
  • Mechanism of Action Methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 19 Feb 2013 Early research is ongoing in United Kingdom (unspecified route)
  • 25 May 2012 Methyltransferase inhbitors are available for licensing as of 25 May 2012 (\http://www.domainex.co.uk\)
  • 24 Feb 2010 Early research in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top